GUANGDONG RAYNOVENT BIOTECH CO LTD has a total of 45 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2015. It filed its patents most often in United States, EPO (European Patent Office) and Taiwan. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are SHIJIAZHUANG SAGACITY NEW DRUG DEV COMPANY LTD, ASCENEURON S A and LUOXIN PHARMACEUTICAL SHANGHAI CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 9 | |
#2 | EPO (European Patent Office) | 6 | |
#3 | Taiwan | 5 | |
#4 | Australia | 4 | |
#5 | Canada | 4 | |
#6 | Republic of Korea | 4 | |
#7 | WIPO (World Intellectual Property Organization) | 4 | |
#8 | China | 2 | |
#9 | Brazil | 1 | |
#10 | Israel | 1 | |
#11 | Mexico | 1 | |
#12 | New Zealand | 1 | |
#13 | Russian Federation | 1 | |
#14 | Singapore | 1 | |
#15 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Organic chemistry methods | |
#5 | Peptides | |
#6 | Special acyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Chen Shuhui | 41 |
#2 | Li Jian | 34 |
#3 | Chen Xiaoxin | 30 |
#4 | Long Chaofeng | 30 |
#5 | Liu Zhuowei | 16 |
#6 | Xie Cheng | 16 |
#7 | Li Peng | 16 |
#8 | Xiong Jian | 15 |
#9 | Chen Kevin X | 15 |
#10 | Wang Jingjing | 14 |
Publication | Filing date | Title |
---|---|---|
WO2021047437A1 | Pharmaceutical composition for treating viral influenza and preparation thereof | |
WO2021012864A1 | Dominant salt forms of pyrimidine derivatives, and crystal forms thereof | |
WO2019170067A1 | Crystal form and salt form of pyridoimidazole compound and preparation method therefor | |
TW201927748A | Amorphous form of pyrrolidine derivative as PPAR agonist and preparation method thereof | |
KR20190056380A | Anti-influenza virus pyrimidine derivative | |
CA3030431A1 | Pyrrolidine derivatives as ppar agonists | |
US2018305361A1 | Crystal form A of 7-(cyclopropylmethyl)-1-(((cis )-4-hydroxy-4-methylcyclohexyl)methyl)-3-methyl-1H-purine-2,6-(3H,7H)-dione for treating liver diseases | |
TW201706268A | Hydroxyl purine compound and application thereof | |
TW201706273A | Hydroxyl purine compound and application thereof |